WO2025257781 - TREATMENT OF SYSTEMIC SCLEROSIS USING ANTI-BAFF-R ANTIBODIES
National phase entry is expected:
Publication Number
WO/2025/257781
Publication Date
18.12.2025
International Application No.
PCT/IB2025/056029
International Filing Date
12.06.2025
Title **
[English]
TREATMENT OF SYSTEMIC SCLEROSIS USING ANTI-BAFF-R ANTIBODIES
[French]
TRAITEMENT DE LA SCLÉROSE SYSTÉMIQUE À L'AIDE D'ANTICORPS ANTI-BAFF-R
Applicants **
NOVARTIS AG
Inventors
D'ANDREA, Peter
GERGELY, Peter
Priority Data
63/660,384
14.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2013 | |
| EPO | Filing, Examination, Granting | 8494 | |
| Japan | Filing, Examination, Granting | 2078 | |
| South Korea | Filing, Examination, Granting | 1871 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,196
Contact Us
Abstract[English]
The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating systemic sclerosis, e.g. diffuse cutaneous systemic sclerosis, by employing molecules that inhibit the B-cell activating factor receptor (BAFF-R), such as anti-BAFF- R antibodies.[French]
L'invention concerne des méthodes, des régimes de traitement, des utilisations, des kits et des thérapies pour traiter la sclérose systémique, par exemple la sclérose systémique cutanée diffuse, par utilisation de molécules qui inhibent le récepteur du facteur d'activation des lymphocytes B (BAFF-R), tels que des anticorps anti-BAFF-R.